|
High grade glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD93 is a transmembrane receptor that is upregulated in tumor vessels in many cancers, including high-grade glioma.
|
29763414 |
2018 |
|
Psoriasis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Increased protein expression of CD93 psoriatic skin and association with the rs2749817 polymorphism suggests that CD93 plays a role in psoriasis disease pathogenesis.
|
28421233 |
2017 |
|
Age related macular degeneration
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, both transmembrane and soluble CD93 are overexpressed in patients with neovascular AMD, indicating that CD93 may represent a potential new antiangiogenic target in the treatment of choroidal neovascularization..
|
27859225 |
2017 |
|
Exudative age-related macular degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD93 as a Potential Target in Neovascular Age-Related Macular Degeneration.
|
27859225 |
2017 |
|
Blood Vessel Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, CD93 is highly expressed in the endothelial cells of tumor blood vessel and faintly expressed in the non-proliferating endothelium.
|
28912033 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We observed that vascular CD93 expression is elevated in NPC and is correlated with T classification, N classification, distant metastasis, clinical stage and poor prognosis (all P < 0.05).
|
27255994 |
2016 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings provide unique insight into the pathogenesis of NPC and underscore the need to explore novel therapeutic targets such as CD93 to improve NPC treatment.
|
27255994 |
2016 |
|
Atherosclerotic lesion
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistent with this, a cd93-deficient mouse model (in addition to apoe deficiency) demonstrated no difference in atherosclerotic lesion development compared with apoe(-/-) cd93-sufficient littermates.
|
27659228 |
2016 |
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Tissue microarray analysis demonstrated that vascular expression of CD93 was correlated with poor survival in a clinical cohort of patients with high-grade astrocytic glioma.
|
26363010 |
2015 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
|
26363010 |
2015 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results identify CD93 as a key regulator of glioma angiogenesis and vascular function, acting via cytoskeletal rearrangements required for cell-cell and cell-matrix adhesion.
|
26363010 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, CD93 expression identifies a predominantly cycling, non-quiescent leukemia-initiating cell population in MLL-rearranged AML, providing opportunities for selective targeting and eradication of LSCs.
|
26387756 |
2015 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
|
26363010 |
2015 |
|
Acute Undifferentiated Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
|
26387756 |
2015 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
|
26363010 |
2015 |
|
Leukemogenesis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD93 expression is functionally required for engraftment of primary human AML LSCs and leukemogenesis, and it regulates LSC self-renewal predominantly by silencing CDKN2B, a major tumor suppressor in AML.
|
26387756 |
2015 |
|
Undifferentiated leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
|
26387756 |
2015 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
|
26363010 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CD93 gene polymorphism is associated with disseminated colorectal cancer.
|
26008729 |
2015 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plasma CD93 concentration is a potential novel biomarker for coronary artery disease.
|
21332844 |
2011 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Lower odds ratios for risk of MI and incidence of CAD were observed in the middle CD93 tertile (142-173 μg L(-1) ): odds ratio (95% confidence interval), 0.69 (0.49-0.97) and 0.61 (0.40-0.94), respectively.
|
21332844 |
2011 |
|
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lower odds ratios for risk of MI and incidence of CAD were observed in the middle CD93 tertile (142-173 μg L(-1) ): odds ratio (95% confidence interval), 0.69 (0.49-0.97) and 0.61 (0.40-0.94), respectively.
|
21332844 |
2011 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
C1q receptor (C1qR) expression was determined by immunofluorescence flow cytometry on neutrophils from paired peripheral blood and synovial fluid samples from 21 patients with rheumatoid arthritis (RA) and 13 patients with other articular diseases (OAD).
|
8349314 |
1993 |